This is an open-label Phase I/IIa study designed to evaluate ART4215, a new first-in-class investigational medicinal product that is a potent and selective inhibitor of deoxyribonucleic acid (DNA) polymerase (pol) theta. ART4215 is being developed as an oral anti-cancer agent for monotherapy treatment of patients with cancers that harbor defects in DNA repair and in combination with anticancer medicines that cause DNA damage.
This clinical trial is evaluating a drug called ART4215 in participants with advanced or metastatic solid tumors. The main goals of this study are to:~Find the recommended dose of ART4215 that can be given safely to participants alone and in combination with talazoparib~Learn more about the side effects of ART4215 alone and in combination with talazoparib~Learn more about the effectiveness of ART4215 alone and in combination with talazoparib~Learn more about the effectiveness of ART4215 alone and in combination with niraparib